# MiLaboratories

> MiLaboratories builds software for immune repertoire analysis and biologics discovery. Its established MiXCR engine processes T- and B-cell receptor sequencing data; Platforma adds a visual, extensible workspace that helps research teams connect analysis to candidate selection. Academic software access is free, while hosted compute and commercial deployment have separate terms.

- **Founded:** 2021
- **Headquarters:** San Francisco, United States
- **Founders:** Stanislav Poslavsky (CEO), Dmitriy Bolotin (CTO), Dmitriy Chudakov (CSO), Alexey Nechaev (COO)
- **Products:** MiXCR, Platforma, Platforma SDK, Platforma Cloud, Immune repertoire RNA kits
- **Notable:** MiXCR was introduced in Nature Methods in 2015., The company says its algorithms are used by eight of the ten largest pharmaceutical companies., Its October 2024 Series A announcement said cumulative funding had reached $10 million.

## Products & services

- **MiXCR** — Licensed software for processing T- and B-cell receptor sequencing data, including clonotype assembly, error correction, quality control and repertoire comparison. Free for qualifying academic research.
- **Platforma** — Visual discovery workspace that combines sequencing analysis with antibody candidate prioritization, multi-omics and translational research workflows; supports private infrastructure deployment.
- **Platforma SDK** — Open source developer kit for packaging computational tools as reusable blocks with interactive interfaces.
- **Platforma Cloud** — Optional usage-priced compute and storage for academic labs.
- **Immune repertoire RNA kits** — RNA kit technology for immune sequencing licensed to Miltenyi Biotec for production and commercialization.

## Achievements

- MiXCR was introduced in Nature Methods in 2015.
- The company says its algorithms are used by eight of the ten largest pharmaceutical companies.
- Its October 2024 Series A announcement said cumulative funding had reached $10 million.
- The Platforma SDK was introduced alongside the 2024 financing announcement.

## Latest updates

- **2026-09** — CEO Stanislav Poslavsky described configurable MiXCR presets for commercial and custom immune sequencing protocols in a company-shared LinkedIn update.
- **2025-04** — ImmuneWatch announced that its DETECT TCR-epitope annotation block was live in Platforma.
- **2024-10** — MiLaboratories announced a Series A and released the Platforma SDK.

## Links

- Website: https://milaboratories.com/
- LinkedIn: https://www.linkedin.com/company/milaboratories/
- Twitter/X: https://x.com/MiLaboratories
- GitHub: https://github.com/milaboratory
- YouTube: https://www.youtube.com/@MiLaboratories
- Bluesky: https://bsky.app/profile/milaboratories.bsky.social

---

Profile page: https://yespress.io/milaboratories
Published by YesPress — https://yespress.io
Last updated: 2026-09-28